PSP Research LLC Makes New $554,000 Investment in Jazz Pharmaceuticals PLC $JAZZ

PSP Research LLC acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 3,258 shares of the specialty pharmaceutical company’s stock, valued at approximately $554,000. Jazz Pharmaceuticals accounts for about 0.5% of PSP Research LLC’s holdings, making the stock its 6th biggest position.

Other institutional investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its stake in Jazz Pharmaceuticals by 11.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after buying an additional 298,815 shares during the period. Ruffer LLP acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth $2,425,000. Essex Investment Management Co. LLC acquired a new position in shares of Jazz Pharmaceuticals during the third quarter worth $2,697,000. Sequoia Financial Advisors LLC acquired a new position in shares of Jazz Pharmaceuticals during the third quarter worth $605,000. Finally, JPMorgan Chase & Co. lifted its position in shares of Jazz Pharmaceuticals by 8.5% during the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock worth $246,092,000 after purchasing an additional 145,865 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Friday, March 27th. Piper Sandler boosted their target price on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an “overweight” rating in a research report on Thursday, March 19th. Wells Fargo & Company boosted their target price on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Morgan Stanley reissued an “overweight” rating and set a $245.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada boosted their target price on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $238.00.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 55,600 shares of the company’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $191.56, for a total value of $10,650,736.00. Following the sale, the executive vice president directly owned 56,862 shares of the company’s stock, valued at $10,892,484.72. This represents a 49.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Norbert G. Riedel sold 3,415 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $192.00, for a total transaction of $655,680.00. Following the sale, the director directly owned 7,024 shares in the company, valued at $1,348,608. This trade represents a 32.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 74,015 shares of company stock valued at $14,180,486 over the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Trading Up 3.4%

JAZZ opened at $237.45 on Wednesday. The stock has a market capitalization of $14.90 billion, a PE ratio of -11,866.57, a P/E/G ratio of 0.41 and a beta of 0.27. The firm’s fifty day moving average price is $199.21 and its 200 day moving average price is $178.13. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. Jazz Pharmaceuticals PLC has a 12-month low of $105.00 and a 12-month high of $238.55.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. As a group, research analysts expect that Jazz Pharmaceuticals PLC will post 20.75 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.